The telmisartan market has experienced significant growth over the past few years due to the growing prevalence of hypertension. Telmisartan is an angiotensin II receptor antagonist used for the treatment of hypertension. It works by blocking the binding of angiotensin II to AT1 receptors, thereby lowering blood pressure. Some of the major advantages of telmisartan include effective hypertension control, reduced cardiovascular complications, organ protection, and good safety profile. The growing geriatric population which is more prone to hypertension has increased the demand for telmisartan globally.
The Global Telmisartan Market is estimated to be valued at US$ 4.20 Bn in 2024 and is expected to exhibit a CAGR of 3.7% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the telmisartan market are Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Mylan N.V., Cipla Ltd., Abbott Laboratories, Cadila Healthcare Ltd, Torrent Pharmaceuticals Ltd., Merck KGaA, Pfizer Inc., Sanofi S.A., Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Macleods Pharmaceuticals Ltd.
Boehringer Ingelheim is one of the leading players in the Telmisartan Market Growth with its brand Micardis being one of the top selling drugs containing telmisartan. The company has a strong distribution network across major markets.
Growing demand for cost-effective treatment options for hypertension is driving the growth of generic versions of telmisartan. The patent expiry of major brands has enabled generic manufacturers to cater to a wider population base.
Technological advances in drug delivery systems are helping enhance the bioavailability and efficacy of telmisartan. Once-daily formulations and fixed-dose combinations with other antihypertensives are gaining popularity.
Market Trends
Increasing focus on fixed-dose combinations - Many companies are developing FDCs of telmisartan with other cardioprotective agents like amlodipine to improve patient compliance. This is expected to boost the demand.
Growth in emerging markets - Countries like India, China, Brazil, and Mexico are witnessing rapid urbanization and lifestyle changes contributing to rising hypertension prevalence. This provides significant opportunities for telmisartan sales.
Market Opportunities
Growing obese and diabetic population - Since obesity and diabetes are independent risk factors for hypertension, their rising global burden presents indirect commercial potential.
E-commerce platforms - Online pharmacies are making healthcare services and medicines more accessible, especially in underserved areas. This creates new sales avenues.
The COVID-19 pandemic has impacted the growth of the Telmisartan market. During the initial phase of the pandemic, restrictions imposed on non-essential medical procedures and visits impacted the demand and supply chain of telmisartan. With lockdowns in place, manufacturing and distribution also faced disruptions causing delays in drug supply. However, with telmisartan used majorly for treatment of hypertension, a chronic condition, demand did not decline sharply.
As the pandemic prolonged, teleconsultations and home deliveries of medicines increased enabling continuity of treatment. Manufacturers also ramped up production gradually to meet the needs. The demand is projected to rise further in the post-COVID era, as recovery in economic activities gains pace. With enhanced focus on preventing comorbidities, prescription of drugs like telmisartan for controlling blood pressure is expected. The market is foreseeing steady growth with projections to reach $4.20 bn by 2025.
In terms of geographical regions, North America currently accounts for the largest share of the global telmisartan market, both in terms of volume and value. This is attributed to factors such rising prevalence of hypertension, robust healthcare infrastructure and greater access to novel drugs and therapies. However, Asia Pacific is emerging as the fastest growing regional market for telmisartan. This growth can be accredited to increasing health awareness, rapidly developing economic conditions and rising healthcare investments in countries like China, India and South Korea.
The telmisartan market in Latin America has also witnessed steady expansion over the past few years. Major factors driving growth include improving medical facilities, rising disposable incomes and growing focus on management of chronic ailments like high blood pressure. Government initiatives to enhance access to affordable treatment augurs well for market players in the region. With COVID-19 emphasizing the need to tackle non-communicable diseases, demand for anti-hypertensives in Latin America is set to surge further in the forthcoming years.
Get more insights on, Telmisartan Market
Get this Report in Japanese Language:
Get this Report in Korean Language:
Explore More Related Article On- General Anesthesia Drugs Market
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
